Dalbalencia in real clinical practice in Spain. a two-year retrospective study.
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: ANGELINI PHARMA ESPAÑA, SL
- Execution start: 07/04/2020
- End of execution: 07/10/2020
- PI: JUAN PASQUAU LIAÑO